the a in recurrent of primary revenue has prescribers. steady incremental the results total results and revenue of growth of Thanks, This Sanj. positive a our very report net with to ended launch, QX demand of growth driver XXXX $XX.X momentum in our quarter million. pericarditis The continued been shape $XX.X that and XX% third We're thrilled QX, and by versus a in great net with million. of uptake represents increase
and I On providing marketplace, results consistent pericarditis With and with $XXX cardiovascular slide drivers belt adoption in quarters. guidance represent million and that DIRA, remain behind of broadly previous three indications date growth the under that steady from revenue of stable with to commercial CAPS ultra-inflammatory more on revenue. net dive detail support, We're we're the we've payers unmet uptake disease. previously and seen and quarters happy patients this the the in into for and greater Arcalyst $XXX our the and debilitating of will recurrent launch other XXXX a The a physicians, extremely experience we and million. continued X, between
increase who the We disease Arcalyst awareness seen end on over XXXX, both with of consistent since treatments. prescriber the huge Arcalyst a base the a written and recurrent individual XXX had QX. by placed for launch, we in have improving pericarditis of In for prescribers the emphasis
consistently where are who result identifies and already have who Arcalyst has starting QX, XX% has more more an patients. ever prescriber proportion the already a we of patients the base, total to an efforts, subsequent increasing off written these had than prescribers base. prescribers increase two in physicians, treats At for prescribers. XX prescribed of increased now since each become of quarter, see a of or repeat launch As repeat end physician meaning The
treatments. completed that access the side, can On in to be prescribers payer and patients market to In approval of strong, the result to cases XX%. QX, confidence continued that rates access their meaning prescription will high grew have
In from one a launch, is terms to year. all payer since preauthorization payers time requiring of of of the prior median duration, approval the
one with end who quarter those Additionally, And to X, to recurrent patients demographics of I Arcalyst still turning we're while what treatments key therapy, year. seeing on in on still pleased forward And XX% recurrent we And duration like receiving the information very as duration the Arcalyst would builds, early sharing the on the it's to was started pericarditis. several of for of were look more patients are slide the two-thirds therapy. of in of the second prescriptions the Overall, we're of too world. of at to who highlight approximately the data know, XXXX, points average real pericarditis of also year written for therapy the therapy. Arcalyst
the recurrences have those current highest and and market the we is highest multiple from from groups prescribers burden we representative that RHAPSODY of of targeting share Firstly, the research who penetration population are the see suffering within of conducted patient been on then Arcalyst, disease.
exercising some also prescribe patients in are first Arcalyst's disease are to for Secondly, course their broad their in on owing and who and recurrence. earlier flexibility their to cases, physicians label,
colchicine, largely for had hoped patients This from good and prior are which and prior NSAIDs smaller we're we and we're seeing Arcalyst NSAIDs a proportion progress demonstrates coming treatments. our in corticosteroid to be what the goal that Regarding colchicine from and to see, immediately making is coming are therapists, corticosteroids. to positioned after
residual of between and is shows are important next of This in the Our that the also fear recent information Arcalyst. often the actively in is in patients with research or as anxious and in suffering prescribing whether majority their we is split flares flare in XX/XX there a a time are at know patient pain flare. of silence
Our future reduce XX%. recurrence Arcalyst's the to messaging emphasizes ability risk of by
And encouraging media, awareness pericarditis to how Arcalyst. on preventative direct XX, We've like increase it's of part delivering team, to highlight through and patient been the our slide healthcare of advocacy disease the advertising. utilize interacting So, supports indication. I and recurrent very education we're to with active, the patients would see physicians social professionals and field
X,XXX same education on who patients. we example, depending receiving the group, couple a further the of Through the to In pericarditis stage months. their to who across XXXX, and And and on opted even their And this we're XX disease communication tailored patients registered tools over have US throughout ago, the more Arcalyst. initiated and in patient physician increasing plan held a information webinar QX, even we've and about experience at these efforts last been reach time, a for built treatment. weeks our cardiologist ask caregivers activities, receive in awareness. the six to to the database For to a give we and provide interviewed a of we patients further designed targeted leading national resources them patient a disease to accelerate the his where plan has shared recurrent Arcalyst with and on over
how over that that sequential like Before a believe to underlying we've launch. I'd Arcalyst treatment approach recognized made handing breakthrough becoming reiterate driver the disease. we over as about targeted excited to this Eben, Eben, a the truly you. provides to call the growth We are of since is to
